Search In this Thesis
   Search In this Thesis  
العنوان
Effects of drugs acting on potassium channels in rotenone-induced dopaminergic cell death in mice /
الناشر
Heba Tallah Ahmed Mohamed Farid Shaaban ,
المؤلف
Heba Tallah Ahmed Mohamed Farid Shaaban
هيئة الاعداد
باحث / Heba Tallah Ahmed Mohamed Farid Shaaban
مشرف / Ezz Eldin Saeed Eldenshary
مشرف / Hala Fahmy Zaki
مشرف / Omar M. Abdelsalam
تاريخ النشر
2018
عدد الصفحات
210 P. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الصيدلة ، علم السموم والصيدلانيات (المتنوعة)
تاريخ الإجازة
19/5/2019
مكان الإجازة
جامعة القاهرة - كلية الصيدلة - Pharmacology and Toxicology
الفهرس
Only 14 pages are availabe for public view

from 251

from 251

Abstract

This study aimed to investigate the effect of KATP channel opening with nicorandil or blockade with glibenclamide on neurodegeneration in mice following systemic rotenone injection. Mice were treated with rotenone (1.5 mg/kg subcutaneously; 3 times/week on days 1, 3, 5) for 3 successive weeks. Starting on the 1st day of rotenone treatment, mice were daily treated intraperitoneally with either nicorandil (6 or 10 mg/kg), glibenclamide (3 or 5 mg/kg) or l-dopa (25 mg/kg). Behavioral examination using the wire hanging and stair tests were performed. Striatal levels of dopamine, tyrosine-hydroxylase, caspases (3, 8, 9), Bcl-2, and tumor necrosis factor-Ü (TNF-Ü) were determined. Rotenone injection resulted in a decrease in motor strength and activity in mice. In addition, striatal apoptosis was evidenced by decreased level of the antiapoptotic protein Bcl-2, the increase in the apoptotic markers caspase 3, 8 and 9 as well as by histopathological alterations. Treatment with glibenclamide and l-dopa exerted a neuroprotective effect as revealed by the increase of Bcl2, tyrosine-hydroxylase and dopamine while decreasing caspase 3, 8, 9 and TNF- Ü immunoreactivity. On the other hand, nicorandil administration didn{u2019}t ameliorate rotenone-induced striatal neurodegeneration. These data suggest an antiapoptotic and anti-inflammatory action for glibenclamide and l-dopa in the rotenone model of Parkinson{u2019}s disease in mice